Abstract 1177P
Background
Sonidegib is a Hedgehog pathway inhibitor approved for the treatment of locally advanced basal cell carcinoma (laBCC) in the US, EU, Switzerland, and Australia, and metastatic BCC (mBCC) in Switzerland and Australia not amenable to curative surgery or radiotherapy. This analysis compared tumour burden reduction using photography or magnetic resonance imaging (MRI) in patients with laBCC that had a time to first tumour response (TFTR) within 6 months of starting treatment.
Methods
The double-blind, multicentre, phase II BOLT study assessed the efficacy and safety of sonidegib 200 mg with laBCC. Tumour burden reduction was assessed using both colour photography and MRI by central review. Tumour response was defined as a >10 mm unidimensional decrease in tumour size. Safety assessments included adverse event (AE) monitoring.
Results
Overall, among 66 patients with laBCC receiving sonidegib 200 mg, TFTR <3 months was achieved by 31 patients per photography and 11 patients per MRI assessment; TFTR from 3 to <6 months was achieved by 8 patients per photography and 12 per MRI. For patients with a TFTR of <3 months, the median (minimum, maximum) percent change from baseline in tumour size was −18.5 (−100.0, 35.9) vs −23.8 (−100.0, −11.9) at 9 weeks, −33.4 (−100.0, 38.5) vs −54.0 (−100.0, −27.1) at 25 weeks, −30.7 (−100.0, 12.0) vs −82.1 (−100.0, −52.9) at 41 weeks, and −29.0 (−100.0, 57.8) vs −82.1 (−100.0, −58.8) at 61 weeks per photography vs MRI, respectively. For patients with a TFTR from 3 to <6 months, the median (minimum, maximum) percent change from baseline in tumour size was not available at 9 weeks, −16.0 (−100.0, 18.1) vs −37.0 (−77.3, −12.5) at 25 weeks, −32.9 (−54.7, 22.3) vs −79.2 (−100.0, −41.5) at 41 weeks, and −35.1 (−46.8, −23.4) vs −77.3 (−100.0, −31.6) at 61 weeks per photography vs MRI, respectively. Sonidegib was well tolerated, and most AEs were Grade 1/2 in severity.
Conclusions
In patients with a TFTR within 6 months of starting treatment with sonidegib, an overall greater reduction in tumour size was reported per MRI assessment vs photography, with photography underestimating the extent of tumour response.
Clinical trial identification
NCT01327053.
Editorial acknowledgement
Writing and editorial support were provided by Duncan McCloskey, PhD, of AlphaBioCom, a Red Nucleus company, and funded by Sun Pharma.
Legal entity responsible for the study
Sun Pharma.
Funding
Sun Pharma.
Disclosure
R. Gutzmer: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Almirall, Amgen, Bristol Myers Squibb, Immunocore, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi Genzyme, Sun Pharmaceutical Industries, Inc., 4SC, Bayer; Non-Financial Interests, Personal, Research Funding: Amgen, Johnson & Johnson, Merck Serono, Novartis; Financial Interests, Advisory Board: Sun Pharmaceutical Industries, Inc. F. Kiecker: Financial Interests, Personal, Research Grant: Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi. C. Loquai: Non-Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche, Novartis, Merck Sharp & Dohme. R. Dummer: Non-Financial Interests, Personal, Advisory Board: Amgen, Bristol Myers Squibb, CatalYm, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Second Genome, Sun Pharmaceutical Industries, Inc., Takeda. A. Hauschild: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, OncoSec, Eisai; Non-Financial Interests, Personal, Research Funding: Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, OncoSec, Eisai. N. Squittieri, R. Arntz, S. Martelli, J. Dierlamm: Financial Interests, Personal, Full or part-time Employment: Sun Pharmaceutical Industries Inc. C. Robert: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Array BioPharma, Bristol Myers Squibb, Merck, Merck Serono, Novartis, Pierre Fabre, Roche.
Resources from the same session
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13